Gamida Cell presented new long term follow-up data and health-related quality of life scores of individuals with omidubicel

October 9th, 2022 by IBF

Gamida Cell (NASDAQ: GMDA), shared new data showing overall survival and disease-free survival of 63% and 56% respectively.